NextCell Pharma publishes its Interim Report 4 2024/2025

October 30, 2025

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 4 for the period June 1, 2025 – August 31, 2025. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. . Please note that the Company's financial year is now 1 January - 31 December. This means that for the year 2025, this Q4 report will be followed by a Year-end report at the end of February 2026, covering the period September-December 2025.

Fourth Quarter (2025-06-01 to 2025-08-31)

Operating income amounted to 2,522 (1,696) TSEK, of which Cellaviva contributed 2,600 (1,643) TSEK.
Net sales amounted to 2,600 (1,643) TSEK.
Profit/loss after financial items amounted to -8,481 (-13,249) TSEK.
Earnings per share* were -0.08 (-0.22) SEK.
Cash and cash equivalents amounted to 38,723 (49,970) TSEK.
Equity ratio** amounted to 86 (83) percent.

Twelve Months (2024-09-01 to 2025-08-31)

Operating income amounted to 11,065 (11,278) TSEK, of which Cellaviva contributed 10,937 (10,665) TSEK.
Net sales amounted to 10,937 (10,665) TSEK.
Profit/loss after financial items amounted to -34,992 (-41,960) TSEK.
Earnings per share* were -0.46 (-1.03) SEK.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the fourth quarter of 2024/2025: 109,746,641 (59,979,085) shares. The average number of shares for the first twelve months of 2024/2025: 76,412,199 (40,814,386) shares. The number of shares in NextCell as of 31 August 2025: 111,392,959 (73,091,327) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the fourth quarter

At the beginning of June, the Company announced the outcome of the exercise of TO2 and resolved on directed share issues to guarantors, Through the exercise of the Warrants and the Directed Issue, the Company will receive a total of approximately SEK 36.6 million before deduction of issue costs. Furthermore, the Board of Directors has resolved on a set-off issue of 1,742,100 shares to the guarantors for payment of the guarantee fee.
The Company announced in early June that all patients in the ongoing ProTrans-Young clinical study had been treated. A milestone that marks the completion of dosing in the company's largest clinical study to date. ProTrans-Young is evaluating the safety and efficacy of the company's lead cell therapy candidate, ProTrans, for the treatment of children and adolescents with newly diagnosed type 1 diabetes.Cell and Gene Therapy (ISCT).
In Mid-July the company summoned to an Extraordinary General Meeting in order to change the company's fiscal year to be aligned with the calendar year.

At the end of August, NextCell announced that the Extraordinary General Meeting had resolved to amend the Articles of Association to reschedule the financial year to be 1 January – 31st December.

Significant events and news after the reporting period

At the beginning of September, NextCell announced that the company’s CFO Patrik Fagerholm is leaving his position and that the recruitment process to find a replacement has begun.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-10-2025 07:30 CET.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com

Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
QVance AB: www.qvance.se

LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.

About NextCell Pharma AB
NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell’s subsidiaries include Cellaviva, Scandinavia’s largest private stem cell bank, and QVance, the Nordic region’s first dedicated provider of quality services for developers of advanced therapies.

Download attachment Read full press release on Cision (external link)

2018-11-12

Earlier announced directed share issue to Nordic Tech House AB registered at the Swedish Companies Registrations Office

NextCell Pharma AB ("NextCell") hereby announces that the directed share issue to Nordic Tech House AB (”NTH”) has been registered at the Swedish Companies Registrations Office (Bolagsverket). The newly issued shares are under lock-up. In total, 260 100 shares have been issued at a subscription price of SEK 5.767 per share, equivalent to 2.3 percent of votes and capital in NXTCL. The shares will be settled retrospectively. After the registration at the Swedish Companies Registrations Office, the total amount of shares in NXTCL are 11 486 456 and the share capital is SEK 2 354 723,48. NTH has

Read more Read more

2018-11-09

Publication of annual report 2017/2018

NextCell Pharma AB hereby, on November 9th, 2018, publishes the annual report for the fiscal year 2017/2018. The annual report is available on the company’s website (www.nextcellpharma.com) and Spotlight Stock Market’s website (www.spotlightstockmarket.com).

Read more Read more

2018-11-05

Application for clinical trial submitted to the Medical Products Agency, ProTrans-2.

NextCell Pharma AB ("NXTCL") today announced that a new application to conduct a clinical trial with ProTrans has been submitted to the Swedish Medical Products Agency. The purpose of the study is to evaluate repeated treatment with ProTrans, including patients with type 1 diabetes who participated in the dose escalating part of the original NXTCL trial. The ongoing clinical trial called ProTrans-1, was initiated with a dose escalation phase for 9 patients all followed for 12 months. After their last visit in the study, patients will be asked if they want to participate in a new study where

Read more Read more

2018-11-02

Update regarding targeted new issue to Nordic Tech House

NextCell Pharma (NXTCL), announces today that the Board, with the authorization of the Annual General Meeting of December 5, 2017, has decided to implement a directed new issue of Nordic Tech House AB ("NTH") of a maximum of approximately SEK 1.5 million. The reasons for the deviation from shareholders' pre-emption rights are to fulfil the company's commitment in accordance with an agreement with Nordic Tech House AB, which was concluded to provide the company with new owners of strategic importance. Current decision replaces previous resolutions on directed new issue from March 13, 2018,

Read more Read more

2018-10-31

Publication of year-end report

NextCell Pharma AB (”NXTCL”, “NextCell”) today, released its year-end report for book year 2017/2018 (September 2017 – August 2018). Twelve Months (2017-09-01 until 2018-08-31) · Net sales amounted to SEK 655 413 (517 203). · Operating result amounted to SEK –14 032 294 (-13 245 206). · Result per share amounted to SEK -0,61 (-0,64). · Cash and bank amounted to SEK 3 115 876 (16 600 937). · Solidity amounted to 59 (88) %. · Net sales amounted to SEK 127 868 (198 765). · Operating result amounted to SEK -3 422 282 (-4 757 996).

Read more Read more

2018-10-25

The Safety Committee recommends proceeding with part 2 of the stem cell trial in type 1 diabetes

The stem cell company NextCell Pharma AB ("NXTCL") today announced that the Data and Safety Monitoring Board recommends Professor Per-Ola Carlsson Academic Hospital, Uppsala University and NXTCL to proceed with the second part of the clinical trial with ProTrans. Patients with type 1 diabetes aged 18-40 years old who had the disease for a maximum of 2 years and who have some own insulin production are candidates to be included in the study. The second part of the ProTrans trial is a Phase-II study with the aim to further evaluate the efficacy and safety of ProTrans. The efficacy of the

Read more Read more

2018-10-01

NXTCL’s Cellaviva brand is expanding into Denmark

NextCell Pharma AB ("NXTCL") announced today, that the Cellaviva brand will expand its operations into Denmark. As of 1st October 2018, Cellaviva will offer family stem cell banking there. The idea of family saving of stem cells is already an established business in Denmark and NXTCL estimates that its entrance into Denmark will allow for a doubling of annual sales for Cellaviva. The establishment fits within the existing budget and does not affect NXTCL's capital requirements. Cellaviva has now decided to expand its operations to Denmark as of 1st October 2018. The company holds all the

Read more Read more

2018-09-20

Redeemed warrants are now registered with the Swedish Companies Registration Office

NextCell Pharma AB ("NXTCL") announced today, 20th September 2018, that the exercised series TO 1 warrants, whose subscription period ended on 13th September 2018, have now been registered with the Swedish Companies Registration Office. A total of 2 720 931 new shares have been registered, which means that the number of shares in NXTCL after registration amounts to 11 226 356. The share capital amounts to SEK 2 301 402.98. Conversion of interim shares to shares is expected to take place on 28th September 2018. Different agents may take a different amount of time to convert, which means that

Read more Read more